Novel oxime derivatives to treat viral infections

Abstract

The present invention relates to novel compounds of the formula (I) having potential to treat viral infections especially related to dengue virus, their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts, their polymorphs, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

Description

[0001] Title: NOVEL OXIME DERIVATIVES TO TREAT VIRAL INFECTIONS FIELD OF INVENTION The present invention relates to novel compounds of the formula (I) having potential to treat viral infections especially related to dengue virus, their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts, their polymorphs, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. Dengue, caused by dengue virus (DENV), is one of the most important arthropod-borne human viral infections in many tropical and subtropical areas. With approximately 390 million infections occurring each year, DENV infection puts global population at high health risk. The DENV genome encodes three structural proteins – the capsid (C), membrane (M), and envelope (E) proteins – and seven nonstructural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. There are four distinct DENV serotypes: DENV-1, DENV-2, DENV-3, and DENV-4 with each capable of infecting person in his life time. Infection with one serotype may provide lifelong immunity against infection with a homologous DENV strain; however, only short-term immunity is maintained against heterologous infections. Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are the life-threatening outcomes of DENV infection. Severe dengue may lead to the plasma leakage, hemorrhagic tendencies, organ failure, shock, and occasionally death. Dengvaxia, is the approved tetravalent live-attenuated dengue vaccine candidate but its usage has been allowed with strict restrictions and it offers high effectiveness in preventing dengue disease caused by DENV serotypes 1– 4 and is safe in people who have had a past dengue infection, i.e., those who are seropositive. US10550123 describes viral replication inhibitors and process to prepare same. WO2021094563, WO2018215315, WO2018178238, WO2017046255, WO2017046258, WO2017167951, WO2016180696 and WO2016113371 describe substituted indole and indoline derivatives for the treatment of dengue disease. WO2019244047 describes N-substituted tetrahydrothienopyridine derivatives and their use thereof. WO2018178240 describes substituted indoline derivatives as dengue viral replication inhibitors. WO2017102014 describes propenamide thiophene derivatives as flavivirus inhibitors and their use. Despite the worldwide spread and the long existence of the dengue disease, there is still no specific antiviral drugs for the treatment or prevention of dengue fever virus infection. Hence, there is a great unmet medical need for therapeutics for the prevention or treatment of viral infections in animals, especially for viral infections caused by Dengue virus. Compounds with good pan anti-viral potency for DENV 1-4, minimal side-effects, a low toxicity and good ADME profile are highly needed. SUMMARY OF THE INVENTION The present invention relates to novel compounds of the general formula (I) having the potential to treat viral infections especially those related to the dengue virus, their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts, their polymorphs, pharmaceutical compositions containing them and methods for their preparation. The compounds of the present invention are useful in the treatment of the human or animal body, by regulation of viral replication. The compounds of this invention are therefore suitable for the treatment of virus-related disorders such as Dengue. EMBODIMENTS OF THE INVENTION The main objective of the present invention is to provide novel compounds of formula (I), their tautomeric forms, their stereoisomers, novel intermediates involved in their synthesis, their suitable pharmaceutically acceptable salts and their polymorphs. In an embodiment is provided a process for the preparation of novel compounds of formula (I), their tautomeric forms, their stereoisomers, novel intermediates involved in their synthesis, their suitable pharmaceutically acceptable salts and their polymorphs. In another embodiment is provided pharmaceutical compositions comprising compounds of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs having pharmaceutically acceptable carriers, solvents, diluents, binder, disintegrant, coating agent, filler, glidant, and / or other suitable excipients. In a further another embodiment is provided the use of the novel compounds of the present invention for the treatment of virus-related disorders such as dengue, by administering a therapeutically effective & non-toxic amount of the compound of formula (I) or their pharmaceutically acceptable salts, or their pharmaceutically acceptable compositions. In yet another embodiment is provided a method of treating virus-related disorders such as dengue using compound of formula (I) or their pharmaceutically acceptable salts, or their pharmaceutically acceptable compositions. DESCRIPTION OF THE INVENTION In the first embodiment, the present invention relates to compounds of the formula (I),

[0002]  Wherein, X represents aryl, heteroaryl or heterocyclyl ring; R1 represents hydrogen, halogen, haloalkyl, (C1-C6)alkyl, heterocyclyl, -OR6; where (C1-C6)alkyl, heterocyclyl are independently unsubstituted or substituted with one or more suitable substituents; Y1 and Y2 independently represent hydrogen, fluoro, (C1-C6)alkyl and -OR6; A and B represent carbocyclic or heterocyclic ring; R2and R3represents hydrogen, hydroxy, cyano, halo, nitro, haloalkyl, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy, -COR6, -COOR6, -OR6, -OSO2CH3, - OCOR6, -S(O)pR6, -NR6R7, -CONR6R7, -N(R6)COR7, -N(R6)COOR7, - N(R6)CONR6R7, -SO2NR6R7, -N(R6)SO2R7; which are independently unsubstituted or substituted with one or more suitable substituents; R4is selected from hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, haloalkyl and heterocyclyl, which are independently unsubstituted or substituted with one or more suitable substituents; R5is selected from haloalkyl, (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, which are independently unsubstituted or substituted with one or more suitable substituents; R6and R7are independently selected from hydrogen, unsubstituted or substituted (C1- C6)alkyl, (C3-C6)cycloalkyl, haloalkyl; R6and R7together with the N atom to which they are attached may form a 5-8 membered heterocyclyl or heteroaryl ring; In an embodiment, when any of the (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- C6)cycloalkyl are substituted; the suitable substitutions on them may be selected from hydrogen, hydroxy, cyano, halo, nitro, haloalkyl, oxo, (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy, -COR6, - COOR6, -OR6, -S(O)pR6, -NR6R7, -CONR6R7, -CON(R6)OR7, -CON(R6)SO2R7, - N(R6)COR7, -N(R6)COOR7, -N(R6)CONR6R7,-SO2NR6R7, -N(R6)SO2R7derivatives; R6 and R7 are same as described above; p represents integers from 0-2; l represents integers from 1-4; m represents integers from 1-5; n represents integers from 1-4. In the second embodiment, the present invention relates to compounds of the general formula (I-A); or pharmaceutically acceptable salt thereof, wherein the groups R1, R2, R3, R4, R5, Y1 and Y2 in formula (I-A) are as described in formula (I). Further preferred embodiments are those disclosed below: Preferred X is selected from aryl; Y1 and Y2 independently represent hydrogen, (C1-C6)alkyl; A and B represents carbocyclic ring; Preferred R1,R2and R3may be selected from the halogen and -OR6; Preferred R4 may be selected from hydrogen, (C1-C6)alkyl; Preferred R5 may be selected from unsubstituted or substituted (C1-C6)alkyl; R6and R7are independently selected from hydrogen, unsubstituted or substituted (C1- C6)alkyl; Preferred substitutions may be selected from cyano, -COOR6, -OR6, -CONR6R7, and - CON(R6)SO2R7; l represents integers from 1-4; m represents integers from 1-5; n represents integers from 1-4. In a further embodiment the groups, radicals described above may be selected from: - the “alkyl” group used either alone or in combination with other radicals, denotes a linear or branched radical containing one to six carbons, selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, amyl, t-amyl, n-pentyl, n- hexyl, and the like; - the “alkenyl” group used either alone or in combination with other radicals, is selected from a radical containing from two to six carbons, more preferably groups selected from vinyl, allyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl and the like; the “alkenyl” group includes dienes and trienes of straight and branched chains; - the “alkynyl” group used either alone or in combination with other radicals, is selected from a linear or branched radical containing two to six carbon atoms, more preferably thienyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1- pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, and the like. The term “alkynyl” includes di- and tri-ynes; - the “cycloalkyl”, or “alicyclic” group used either alone or in combination with other radicals, is selected from a cyclic radical containing three to six carbons, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like; - the “haloalkyl” group is selected from an alkyl radical, as defined above, suitably substituted with one or more halogens; such as fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl or hexyl groups; - "halo" or "halogen" by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom; - the “aryl” or “aromatic” group used either alone or in combination with other radicals, is selected from a suitable aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused, more preferably the groups are selected from phenyl, naphthyl, tetrahydronaphthyl, indane, biphenyl, and the like; - the “carbocyclic” group used either alone or in combination with other radicals, is selected from groups as described in “cycloalkyl” or “aryl” or “aromatic”. - the “heterocyclyl” or “heterocyclic” group used either alone or in combination with other radicals, is selected from suitable saturated, partially saturated or unsaturated aromatic or non-aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms selected from nitrogen, sulfur and oxygen, more preferably selected from aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 4- methylpiprrazinyl, 4-hydroxypiperidinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2- oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl, dioxothiomorpholinyl, 2-oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazolidinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidonyl, azaquinazolinoyl, thienopyrimidonyl, quinazolonyl, pyrimidonyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, thieno piperidinyl, and the like; In one embodiment, the heterocycle group, wherever applicable, may consists of appropriate number of carbon atoms and include from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)p, p = 0-2; - the “heteroaryl” or “heteroaromatic” group used either alone or in combination with other radicals, is selected from suitable single or fused mono, bi or tricyclic aromatic heterocyclic radicals containing one or more hetero atoms selected from O, N or S, more preferably the groups are selected from pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, azaindolyl, azaindolinyl, pyrazolopyrimidinyl, azaquinazolinyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, triazinyl, benzimidazolyl, benzotriazolyl, phthalazynil, naphthylidinyl, purinyl, carbazolyl, phenothiazinyl, phenoxazinyl, benzoxazolyl, benzothiazolyl and the like; - the “aralkyl” group used either alone or in combination with other radicals, is selected from groups containing an aryl radical, as defined above, attached directly to an alkyl radical, as define above, more preferably groups selected from benzyl, phenethyl, and the like; - the “heterocyclylalkyl” group used either alone or in combination with other radicals, is selected from groups containing an heterocyclyl radical, as defined above, attached directly to an alkyl radical, as define above; - the “alkylsulfonyloxy” group used either alone or in combination, refers to an alkylsulfonyl group attached directly to an oxygen atom, wherein a suitable alkyl group as defined above is attached to a sulfonyl radical; - the “one or more suitable substituents” used either one or more suitable substituents substituted on single carbon or it may be substituted on more than one carbon; - the term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. Substitution selected from hydrogen, deuterium, hydroxy, cyano, halo, nitro, haloalkyl, oxo, (C1-C6)alkyl, (C3-C6)cycloalkyl, aminoalkyl, alkoxyalkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy; - the term “stereoisomers” used anywhere in the specification indicates that compounds of the present invention show (R) and (S) configuration - the term "polymorph" refers to the ability of the compound of the invention to exist in more than one form or crystal structure. Suitable groups and substituents on the groups may be selected from those described anywhere in the specification. Preferred compounds according to the present invention include but are not limited to: 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; 3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; 2-(((3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1-yl)ethyl)amino)- 5-methoxybenzylidene)amino)oxy)-2-methylpropanoic acid; 3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)acetonitrile; 3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; 2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2-((3-(1-(((1- hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1- one; 2-(4-chlorophenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(1-((2-hydroxyethoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; 3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; 2-(4-chloro-2-methoxyphenyl)-2-((3-(1-((2-hydroxyethoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; 2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- ((3-(1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1- yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; 2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2-((3-(1-((2- hydroxyethoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- ((3-(1-((2-hydroxyethoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one; 2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2-((3-(1-((3- hydroxy-3-methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- ((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1- one; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)acetonitrile; 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)acetonitrile; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propenamide; (2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propenamide; 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N-(methylsulfonyl)propenamide; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-N-(cyanomethyl)-2- methylpropanamide; (2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-N-(cyanomethyl)-2- methylpropanamide; (2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2- methylpropanoyl)glycine; 3-(((1-(3-((1-(4-chlorophenyl)-2-(indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; 2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (+)-3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (-)-3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (+)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (-)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (+)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (-)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (+)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (-)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propenamide; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propenamide; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N-(methylsulfonyl)propanamide; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N-(methylsulfonyl)propanamide; (+)-3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (-)-3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (+)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (-)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (+)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (-)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (+)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (-)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (+)-2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2-((3-(1- (((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)ethan- 1-one; (-)-2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2-((3-(1- (((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)ethan- 1-one; (+)-2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1- yl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-((3-(1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)- 5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)- 5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1- yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1- yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin- 1-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin- 1-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2-((3-(1- ((3-hydroxy-3-methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one; (-)-2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2-((3-(1- ((3-hydroxy-3-methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1- yl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1- one; (+)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (-)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)- 2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile. The novel compounds of this invention may be prepared using the reactions and techniques as shown in scheme below and described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being affected. It is understood by those skilled in the art that the nature and order of the synthetic steps presented may be varied for the purpose of optimizing the formation of the compounds of the present invention. It will also be well appreciated that one or more of the reactants may be protected and de- protected for facile synthesis by techniques known to persons skilled in the art. It will also be appreciated that one or more of the compounds of the present invention may exist in stereoisomeric and / or diastereomeric forms. Such stereoisomers and / or diastereoisomers as well as their optical antipodes are to be construed to be within the scope of the present invention. It will also be well appreciated that one or more of these compounds may be converted to their salts and other derivatives based on the specific groups present on the compounds, which can be well comprehended by persons skilled in the art. Such salts and / or other derivatives, as the case may be should also be construed to be within the scope of the present invention. Scheme 1: Synthesis of compounds of general formula (I)

[0003] The compounds of the general formula (II) can be prepared using general techniques available in the literature to prepare indoline derivatives. Compounds of the general formula (III) can be prepared by alpha halogenation of corresponding acetic acid derivatives using various techniques available in the literature. Compounds of the general formula (IV) can be obtained by coupling (II) with (III) using various amide bond formation techniques known in the art such as described in Tetrahedron 2005, 61, 10827 with appropriate modifications as necessary. The compounds of the general formula (I) can be obtained by reacting compounds of the formula (IV) with (V) in the presence of bases such as triethyl amine, diisopropyl ethyl amine etc, in solvents such as DMF, acetonitrile etc. Scheme 2: Synthesis of compounds of general formula (I)

[0004] Alternatively, compounds of the formula (I) can be obtained by following scheme 2. The compounds of the general formula (VII) can be prepared by coupling compounds of the general formula (VI) and (V) by following a similar method as described in scheme 1 for coupling of compounds of formula (IV) and (V). Compounds of the general formula (VIII) can be obtained by deprotection using alkaline hydrolysis (PG = Me or Et) or debenzylation (PG = Bn) using hydrogenation in the presence of Pd-C. Compounds of the general formula (I) are then obtained by coupling (II) with (VIII) using various amide bond formation techniques known in the art such as described in Tetrahedron 2005, 61, 10827 with appropriate modifications as necessary. Scheme 3: Synthesis of intermediates of general formula (V) Compounds of the general formula (V) can be prepared as shown in scheme 3. Compounds of the formula (X) can be prepared by treating (IX) with hydroxylamine hydrochloride in an alcoholic solvent. The compound of the general formula (XII) can be obtained by coupling (X) with compound (XI) using general nucleophilic displacement techniques available in the literature. Compounds of the formula (V) are prepared by using a reducing agent like stannous chloride in ethyl acetate or hydrogenation in the presence of Pd-C. The invention is explained in greater detail by the examples given below, which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention. The1H NMR spectra were recorded on a Brucker Avance-400 spectrometer (400 The chemical shifts (δ) are reported in parts per million (ppm) relative to Tetramethyl silane (TMS), in either CDCl3or DMSO-d6solution. Mass spectra (ESI- MS) were obtained on Shimadzu LC-MS 2010-A spectrometer. List of Abbreviations PG: Protecting Group L: Leaving Group DCC: Dicyclohexyl carbodiimide DMAP: 4-(Dimethylamino)pyridine DIPE: Diisopropyl ether BH3: Borane EDC: Ethylene dichloride HMPA: Hexamethylphosphoramide TFA: Trifluoroacetic acid CDCl3: Deuterated chloroform DMF: Dimethyl formamide DCM: Dichloromethane DMSO: Dimethyl sulfoxide DMSO-d6: Hexadeuterodimethyl sulfoxide EDC: N-(3-Dimethyl aminopropyl)-N’-ethyl carbodiimide HCl: Hydrochloric acid NaOH: Sodium hydroxide TEA: Triethyl amine 1H NMR: Proton Nuclear Magnetic Resonance h: Hour(s) RT: room temperature [25-300C] min: Minute(s) J: Coupling constant in units of Hz Hz: Hertz Preparation of intermediates of formula (II) Intermediate-1: Preparation of 6-(trifluoromethoxy)indoline (II-1) To a stirring solution of cyano mmol) and benzyl alcohol (50.9 g, 470 mmol) in DCM (250 ml) was added DCC (121 g, 588 mmol) and DMAP (7.18 g, 58.8 mmol) in DCM (250 ml) dropwise over the period of 1 h at 0°C. The resulting mixture was stirred at room temperature for 16 hrs. After completion of reaction, the reaction mixture was filtered and filter cake was washed with 100 ml DCM. The filtrate was evaporated under reduced pressure to get oily material which was dissolved in 3 X 300 ml diisopropyl ether, stirred at room temperature for 1 h and filtered. The filtrate was evaporated under reduced pressure to get the title product. ESI-MS (m / z): 174.1 (M-H). Step 2: Preparation of benzyl 2-cyano-2-(2-nitro-4-(trifluoromethoxy)phenyl)acetate 1 (65.3 g, 373 mmol) and 1- mmol) in DMF (450 ml) was added potassium carbonate (86 g, 621 mmol) at room temperature. The resulting mixture was stirred at 45 °C for 16 hrs. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with brine solution, evaporated under reduced pressure and purified by column chromatography to get the title product. ESI-MS (m / z): 379.06 (M- H). Step 3: Preparation of 6-(trifluoromethoxy)-1H-indole from step 2 (25 g, 65.7 mmol) in was added 10% Pd / C (4.1 gm, 39.4 mmol) at room temperature. The resulting mixture was stirred in a hydrogenator at room temperature under hydrogen pressure (60 psi) for 6-8 hrs. After completion of reaction, the reaction mixture was filtered through a pad of celite and filter cake was washed with ethyl acetate. The filtrate was diluted with water and extracted by ethyl acetate. The organic layer was separated, washed with dilute sodium carbonate solution followed by water and evaporated under reduced pressure. Obtained material was purified by column chromatography to get the title product. ESI-MS (m / z): 200.05 (M- H). Step 4: Preparation of 6-(trifluoromethoxy)indoline To a stirred solution of the step 3 (26 g, 129 mmol) in ethanol (182 ml) was added 8M BH3- mmol) dropwise at 0°C. 5N HCl (364 ml) was slowly added in 90 min while maintaining the temperature below 10°C. The reaction mixture was stirred at 0°C for 2 hrs. After completion of reaction, water (364 ml) was added and the mixture was basified to pH 8-9 with 10M NaOH (364 ml) maintaining the temperature below 20°C. The organic layer was washed with water (twice), evaporated under reduced pressure and purified by column chromatography to get the title product.1H NMR (DMSO-d6): 7.06-7.04 (d, 1H), 6.41-6.36 (m, 2H), 5.87 +. benzene (50 g, 207 mmol) and diethyl malonate (37.90 ml, 101 mmol) in dry DMF (500 ml) was added cesium carbonate (101 g, 310 mmol) and the resulting mixture was stirred at 80°C for 3-4 hrs. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 366.03 (M+H)+. Step 2: Preparation of 2-(2-nitro-4-(trifluoromethoxy)phenyl)acetic acid To a stirring solution of the step 1 (46.35 g, 127 mmol) in methanol (400 mL) was added 100 ml aqueous solution of sodium hydroxide (20.30 g, 508 mmol) and the resulting mixture was stirred at 80°C for 4 hrs. After the complete conversion of starting material, the reaction mixture was diluted with cold water and acidified with dilute HCl. The solid obtained was filtered and washed with water to get the title product. ESI-MS (m / z): 266.03 (M+H)+. Step 3: Preparation of methyl 2-(2-nitro-4-(trifluoromethoxy)phenyl)acetate To a stirring solution of the 2 (33 g, 124 mmol) in DCM (330 mL) was added Oxalyl chloride (6.31 ml, 73.5 mmol) at 00C. over a period of 10 mins and the resulting mixture was stirred for 2 hrs at room temperature. The reaction mixture was cooled to 0°C and 100 mL of methanol was added dropwise and stirred for 2 hrs at room temperature. After complete conversion of starting material, the reaction mixture was diluted with cold water. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 280.05 (M+H)+. Step 4: Preparation of methyl 2-methyl-2-(2-nitro-4- (trifluoromethoxy)phenyl)propanoate 3 (5.00 g, 17.91 mmol) in dry DMF (310 ml) was added sodium hydride (60%) (2.04 g, 53.7 mmol) at 0°C and the resulting mixture was stirred at 0°C for 5 mins. To this was added methyl iodide (3.20 ml, 53.7 mmol) and reaction stirred for 1 hr at 25°C. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. MS (m / z): 308.10 (M+H)+. Step 5: Preparation of 3,3-dimethyl-6-(trifluoromethoxy)indolin-2-one 4 (4.76 g, 15.49 mmol) in acetic was g, and the resulting mixture was stirred at 100°C for 2 hrs. After the complete conversion of starting material, the reaction mixture was filtered through celite and washed with ethyl acetate. The organic layer was distilled out and diluted with cold water. The solid obtained was filtered, washed with water, dried and column purified to get the title product. ESI-MS (m / z): 246.05 (M+H)+. Step 6: Preparation of 3,3-dimethyl-6-(trifluoromethoxy)indoline To a stirring suspension of (1.896 g, 50 mmol) in dry THF (20 ml) at 0°C was added solution of the product obtained from step 5 (3.50 g, 14.27 mmol) in dry THF (20 ml) and the resulting mixture was stirred at 60°C for 2 hrs. After the complete conversion of the starting material, the reaction mixture was diluted with 10% aq. NaOH and stirred for 1 h at RT. The reaction mixture was filtered through celite. Filtrate was washed with water, evaporated under reduced pressure, dried and column purified to get the title product. ESI-MS (m / z): 232.00 (M+H)+Preparation of intermediates of formula (III) Preparation of 2-bromo-2-(4-chlorophenyl)acetic acid (III-1) To a stirring solution of the 2-(4- )acetic acid (10 g, 58.6 mmol) in dry CCl4 (100 ml) was added NBS (11.48 g, 64.5 mmol) followed by AIBN (0.48 g, 2.93 mmol) and the resulting mixture was refluxed for 12 hrs. After the complete conversion of the starting material, the reaction mixture was cooled at 0°C and the precipitated solid was filtered, filtrate was separated, washed with water and dried under reduced pressure to get the title product. ESI-MS (m / z): 248.96 (M-H). Preparation of intermediates of formula (IV) Preparation of Preparation of 2-bromo-2-(4-chlorophenyl)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one (IV-1) To a stirring acetic acid (4.72 g, 18.9 mmol) in DCM (30 ml) was added EDC (3.40 g, 17.7 mmol) , intermediate II-1 (2.4 g, 11.8 mmol) and DMAP (0.144 g, 1.181mmol) at 0°C. The resulting mixture was stirred at room temperature for 2 h. After completion of reaction, the reaction mixture was diluted with cold water and extracted by DCM. The organic layer was washed with water, evaporated under reduced pressure and purified by column chromatography to get the title product.1H NMR (CDCl3): 8.22 (s, 1H), 7.52-7.50 (m, 2H), 7.43-7.34 (m, 2H), 7.28-7.18 (m, 1H), 6.96-6.93 (m, 1H), 5.59 (s, 1H), 4.37-4.30 (m, 1H), 4.15-4.05 (m, 1H), 3.30-3.14 (m, 2H). Using appropriate starting materials and suitable modifications of the process described for the preparation of intermediate IV-1 including suitable addition and / or deletion of steps as may be necessary, well within the scope of a person skilled in the art; the following intermediates (Table 1) were prepared in an analogues manner. Table-1 Intermediates Structure ESI-MS(m / z): (M+H)+IV 2 p p Preparation of tert-butyl 2-(((1-(3-amino-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoate (V-1) Step 1: Preparation of 3- To a stirring solution of the 3,5-dinitrobenzoic acid (20 g, 94 mmol) in dry HMPA (200 ml) was added lithium methanolate (14.32 g, 377 mmol) and the resulting mixture was stirred for 16 hrs at RT and then at 100°C for 8 hrs. After complete conversion of starting material, the reaction mixture was diluted with cold water, acidify with dil. HCl and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 196.06 (M-H) Step 2: Preparation of 3-methoxy-5-nitrobenzoyl chloride To a stirring solution of the from step 1 (2.4 g, 12.17 mmol) in dry DCM (20 ml) was added oxalyl chloride (1.3 ml, 18.26 mmol) and the resulting mixture was stirred for 2 hrs at RT. Excess solvent was distilled out to get the crude product which was directly used for the next step. Step 3: Preparation of 1-(3-methoxy-5-nitrophenyl)ethan-1-one 13.36 mmol) in toluene (30 ml) was added magnesium chloride (0.74 g, 7.79 mmol) followed by triethyl amine (0.72 ml, 27.8 mmol) and the reaction mixture was stirred at RT for 1h. To this, the product obtained from step 2 (2.4 g, 11.13 mmol) in toluene (12 mL) was added and the reaction mixture was stirred at RT for 12 hrs. After the complete conversion of the starting material, the reaction mixture was diluted with cold water and the organic layer was separated. The organic layer was distilled out to get the crude product which was dissolved in a mixture of DMSO (30 ml) and water (5 ml) and heated at 150°C for 4 hrs. After complete conversion of starting material, the reaction mixture was diluted with cold water, and precipitated solid was filtered and dried to get title product. ESI- MS (m / z): 196.02 (M+H)+Step 4: Preparation of 1-(3-methoxy-5-nitrophenyl)ethan-1-one oxime To a stirring solution of the step 3 (700 mg, 3.59 mmol) in water (15 ml) was added sodium acetate (0.915 g, 16.38 mmol) followed by hydroxylamine hydrochloride (1.2 g, 17.93 mmol) and the resulting mixture was stirred at 100°C for 2 hrs. After the complete conversion of the starting material, the reaction mixture was cooled up to 10°C and the precipitated solid was filtered to get the title product. ESI- MS (m / z): 211.07 (M+H)+Step 5: Preparation of tert-butyl 2-(((1-(3-methoxy-5- nitrophenyl)ethylidene)amino)oxy)-2-methylpropanoate To a stirring solution of the 4 (2.5 g, 11.8 mmol) and tert- butyl 2-bromo-2-methylpropanoate (3.98 g, 17.8 mmol) in dry DMF (10 ml) was added potassium carbonate (2.96 g, 21.41 mmol) and the resulting mixture was stirred at 90°C for 4 hrs. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. Organic layer was separated, washed with water and evaporated under reduced pressure to get title product. ESI-MS (m / z): 353.15 (M+H)+Step 6: Preparation of tert-butyl 2-(((1-(3-amino-5-methoxyphenyl) ethylidene) amino) oxy)-2-methylpropanoate To a stirring solution of t tep 5 (0.5 g, 1.542 mmol) in rectified spirit (10 ml) was added iron powder (2.046 g, 10.79 mmol) followed by ammonium chloride (2.046 g, 10.79 mmol) and the resulting mixture was stirred at 80°C for 4 hrs. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water and evaporated under reduced pressure to get the title product.1H NMR (DMSO- , -2- Step 1: Preparation of To a stirring solution of the 3- acid (10 g, 150.7 mmol) in dry DCM (100 mL) was added oxalyl chloride (11.12 ml, 152 mmol) portion-wise over 10 mins and the resulting mixture was stirred for 2 hrs at RT. The reaction mixture was cooled to 0°C and 15 mL of methanol was added dropwise and it was stirred for 2 hrs at RT. After the complete conversion of the starting material, the reaction mixture was diluted with cold water and the organic layer was separated. The organic layer was distilled out to get the title product. Step 2: Preparation of 3-methoxy-5-nitrobenzaldehyde To a stirring solution of obtained g, 170.1 mmol) in dry THF (300 ml) was added DIBAL-H in toluene (107 g, 188.2 mmol) dropwise at -78°C. The reaction mixture was stirred for 1 hr at the same temperature. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 182.06 (M+H)+Step 3: Preparation of 3-methoxy-5-nitrobenzaldehyde oxime To a stirring solution of the step 2 (0.5 g, 2.76 mmol) in water (5 ml) was added sodium acetate (1.83 g, 27.6 mmol) followed by hydroxylamine hydrochloride (0.959 g, 13.8 mmol) and the resulting mixture was stirred at 100°C for 2 hrs. After complete conversion of starting material, the reaction mixture was cooled up to 10°C and the precipitated solid was filtered to get the title product. ESI-MS (m / z): 197.05 (M+H)+Step 4: Preparation of tert-butyl -2-(((3-methoxy-5-nitrobenzylidene)amino)oxy)-2- methylpropanoate To a stirring solution of the product obtained from step 3 (15 g, 76 mmol) and tert- butyl 2-bromo-2-methylpropanoate (21.4 ml, 115 mmol) in dry DMF (100 ml) was added potassium carbonate (19.02 g, 138 mmol) and the resulting mixture was stirred at 90°C for 4 hrs. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. Step 5: Preparation of tert-butyl -2-(((3-amino-5-methoxybenzylidene)amino)oxy)-2- methylpropanoate (9 g, 26.6 mmol) in rectified spirit (100 ml) was added iron powder (8.91 g, 160 mmol) followed by ammonium chloride (8.54 g, 160 mmol) and the resulting mixture was stirred at 80°C for 4 hrs. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water and evaporated under reduced pressure to get the title product.1H NMR (CDCl3): 7.97 (s, 1H), 6.55-6.52 (m, 2H), 6.27-6.26 (t, 1H), 3.75 (s, 3H), (s, 2H), 1.58 (s, 6H), 1.52 (s, 9H). ESI-MS (m / z): 309.1 (M+H)+. Preparation of 1-(3-amino-5-methoxyphenyl)ethane-1-one O-(2-hydroxyethyl) oxime (V-3) 1-one O-(2-hydroxyethyl) oxime To a stirring solution of 1 than-1-one oxime (1.0 g, 4.76 mmol) and 2-bromoethan-1-ol (0.4 ml, 5.71 mmol) in dry DMF (10 ml) was added cesium carbonate (3.88 g, 11.82 mmol) and the resulting mixture was stirred at 90°C for 4 hrs. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water and evaporated under reduced pressure to get the title product. ESI-MS (m / z): 255.09 (M+H)+Step 2: Preparation of 1-(3-amino-5-methoxyphenyl)ethan-1-one O-(2-hydroxyethyl) oxime 1 (1 g, 3.93 mmol) in ethyl acetate (20 ml) was added stannous chloride (4.46 g, 19.67 mmol) and the resulting mixture was stirred at 60°C for 4 hrs. After complete conversion of starting material, the reaction mixture was diluted with aqueous ammonia and the organic layer was decanted. The organic layer was dried and distilled out to get the title product1H NMR (DMSO-d6): 6.49-6.48 (t, J=1.6 Hz, 1H), 6.35-6.34 (t, J=1.6 Hz, 1H), 6.18-6.17 (t, J=2 Hz, 1H), 5.18 (s, 2H), 4.69-4.67 (t, J=5.6 Hz, 1H), 4.12-4.09 (t, J=5.2 Hz, 2H), 3.68 (s, 3H), 3.66-3.62 (q, J=5.5 Hz, 2H), 2.11 (s, 3H). ESI-MS (m / z): 225.2 (M+H)+. Using appropriate starting materials and suitable modifications of the process described for the preparation of intermediates V-1 to V-3 including suitable addition and / or deletion of steps as may be necessary, well within the scope of a person skilled in the art; the following intermediates (Table 2) were prepared in an analogues manner. Table-2 Intermediates Structure ESI-MS(m / z): (M+H)+V-4 220.12 Preparation of ethyl 3-(((1-(3-amino-5-methoxyphenyl)ethylidene)amino)oxy) propanoate (V-11) Step 1: Preparation of ethyl 3-(((1-(3-methoxy-5-nitrophenyl) ethylidene) amino)oxy) propanoate To a stirring solution of 1-one oxime (30 g, 143 mmol) and ethyl acrylate (300 ml) was added TPP (7.49 g, 28.5 mmol) and the resulting mixture was stirred at 100°C for 45 hrs. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 311.7 (M+H)+Step 2: Preparation of ethyl 3-(((1-(3-amino-5-methoxyphenyl) ethylidene) amino) oxy) propanoate To a stirring solution of the 1 (12.0 g, 38.7 mmol) in ethyl acetate (120 ml) was added stannous chloride (36.7 g, 193 mmol) and the resulting mixture was stirred at 60°C for 4 hrs. After completion of the reaction, the reaction mixture was diluted with aq. ammonia and the organic layer was decanted. The organic layer was dried and distilled out to get the title product.1H NMR (DMSO-d6): 6.48- 6.47 (t, J=1.6 Hz, 1H), 6.35-6.34 (t, J=1.6 Hz, 1H), 6.19-6.18 (t, J=1.6 Hz, 1H), 5.19 (s, 2H), 4.33-4.30 (t, J=6 Hz, 2H), 4.11-4.06 (q, J=7.2 Hz, 2H), 3.72 (s, 3H), 2.70-2.67 (t, J=6 Hz, 2H), 2.08 (s, 3H), 1.20-1.16 (t, J=6.8 Hz, 3H). ESI-MS (m / z): 281.15 (M+H)+. Preparation of 3-(((1-(3-amino-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile (V-12) Prepared using a similar proc 1 by using acrylonitrile instead of ethyl acrylate. ESI-MS (m / z): 234.14 (M+H)+. Preparation of intermediates of formula (VI) Preparation of methyl 2-bromo-2-(4-chloro-2-methoxyphenyl)acetate (VI-1) Step 1: Preparation of methyl 2-(4-chloro-2-methoxyphenyl)acetate To a stirring solution of 2-(4- acetic acid (2.5 g, 10.02 mmol) in dry DCM (15 ml) was added oxalyl chloride (1.03 mL, 12.02 mmol) and the resulting mixture was stirred at RT for 1 hr. The reaction mixture was cooled to 0°C and methanol (0.64 mL, 20.04 mmol) was added to the reaction mixture and stirred for 4 hrs at RT. After the complete conversion of the starting material, the reaction mixture was diluted with cold water and the organic layer was separated. The organic layer was distilled out to get the title product. ESI-MS (m / z): 215.13 (M+H)+Step 2: Preparation of methyl 2-bromo-2-(4-chloro-2-methoxyphenyl)acetate Prepared using a similar process as described for intermediate III-1 using methyl 2-(4- chloro-2-methoxyphenyl) acetate as starting material. ESI-MS (m / z): 292.95 (M+H)+Preparation of compounds EXAMPLE 1 Preparation of 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid Step 1: -2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoate To a stirring solution of product obtained from intermediate IV-1 (0.5 g, 1.150 mmol) and and intermediate V-1 (0.371 g, 1.150 mmol) in DMF (10 ml) was added TEA (0.481 ml, 3.45 mmol) at room temperature. The resulting mixture was stirred at 70 °C for 16 h. After completion of reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with brine solution, evaporated under reduced pressure and purified by column chromatography to get the title product. ESI-MS (m / z): 676.25 (M+H)+. Step 2: Preparation of 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy) indolin-1-yl)ethyl)amino)-5-methoxyphenyl) ethylidene) amino) oxy)-2- methylpropanoic acid 0.444 mmol) in DCM (5 mL) was added TFA (0.239 ml, 3.11 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 4 hrs. After complete conversion of starting material, the reaction mixture was diluted with cold water and extracted with DCM. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product. 1H NMR (DMSO-d6): 8.04 (s, 1H), 7.58-7.56 (d, J= 8.4 Hz, 2H ), 7.46-7.44 (d, J= 8.4 Hz, 2H), 7.34-7.32 (m, 1H), 7.30-7.29 (m, 1H), 7.02-7.00 (m, 1H), 6.63 (s, 1H), 6.39- 6.37(d, J= 8.0 Hz, 2H ), 5.77 (s, 1H ), 4.55-4.54 (t, J=2.0 Hz, 1H), 4.05-4.03 (m, 1H ), 3.66 (s, 3H), 3.15-314 (m, 2H), 2.10 (s, 3H), 1.48 (s, 6H). ESI-MS (m / z): 620.20 (M+H)+. EXAMPLE 2 Preparation of 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid Step 1: 2-methoxyphenyl)-2- methoxy-2-oxoethyl) amino)-5-methoxyphenyl) ethylidene) amino)oxy)-2- methylpropanoate To a stirring solution of VI-1 (400 mg, 1.36 mmol) in DMF (15 mL) was added intermediate V-1 (439 mg, 1.36 mmol) followed by triethyl amine (0.28 mL, 2.04 mmol) and the resulting mixture was heated at 80°C for 3 hr. After the complete conversion of starting material, the reaction mixture was diluted with cold water and extracted with ethyl acetate. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product. ESI-MS (m / z): 535.03 (M+H)+Step 2: Preparation of 2-((3-(1-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-2-(4-chloro-2-methoxyphenyl)acetic acid To a stirring solution of th (600 mg, 1.12 mmol) in 50% methanol: THF (10 mL) was added 4 ml aqueous solution of sodium hydroxide (135 mg, 3.36 mmol) and the resulting mixture was stirred at 40°C for 4 hrs. After complete conversion of starting material, the reaction mixture was diluted with cold water, acidify with aqueous HCl and extracted with DCM. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product. ESI-MS (m / z): 521.03 (M+H)+Step 3: Preparation of tert-butyl 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2- (6-(trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoate To a stirring solution mg, 0.49 mmol) in DMF (5 ml) was added intermediate II-1 (112 mg, 0.49 mmol) followed by HATU (148 mg, 1.45 mmol) and DIPEA (0.26 mL, 1.47 mmol) at 0-10°C. The resulting mixture was stirred at the same temperature for 1 hr. After completion of the reaction, the reaction mixture was diluted with cold water and extracted by ethyl acetate. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product. Step 4: Preparation of 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid To a stirring solution of mg, 0.45 mmol) in DCM (15 mL) was added TFA mg, mixture was stirred at room temperature for 4 hrs. After complete conversion of starting material, the reaction mixture was diluted with cold water and extracted with DCM. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product.1H NMR (CDCl3): 8.18 (s, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H), 6.99- 6.90 (m, 3H), 6.57 (d, J = 1.6 Hz, 2H), 6.33-6.32 (m, 1H), 6.71 (s, 1H), 4.32 (m, 1H), 3.98 (s, 3H), 3.90-3.87 (m, 1H), 3.77 (s, 3H), 3.25-3.23 (m, 1H), 3.13-3.10 (m, 1H), 2.25 (s, 3H), 1.59 (s, 3H), 1.55 (s, 3H). ESI-MS (m / z): 650.20 (M+H)+EXAMPLE 3 Preparation of 3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid Step 1: Preparation of ethyl 3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoate IV-1 (280 mg, 0.644 was mg, 0.58 mmol) followed by triethylamine (0.27 ml, 1.93 mmol) and the resulting mixture was stirred at 80°C for 3 hrs. After completion of the reaction, the reaction mixture was diluted with cold water and extracted with ethyl acetate. The organic layer was separated, washed with water, evaporated under reduced pressure, and purified by column chromatography to get the title product. ESI-MS (m / z): 635.04 (M+H)+Step 2: Preparation of 3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid To a stirring mmol) in THF (0.5 ml) was added LiOH (4.79 mg, 0.199 mmol) in water (0.25 ml), and the reaction was stirred at 25°C for 2 hrs. After completion of the reaction, it was diluted with water and acidified by diluting HCl to pH=3. The product was extracted with ethyl acetate and purified by column chromatography to get the desired product1H NMR (DMSO- d6): 8.20 (s, 1H), 7.47 (dd, J = 2.0 and 6.8 Hz, 2H), 7.36 (dd, J = 2.0 and 4.0 Hz, 2H), 7.14 (d, J = 8.4 Hz, 1H), 6.90 (dd, J = 0.8 and 8.0 Hz, 1H), 6.57 (d, J = 1.6 Hz, 2H), 6.22 (d, J = 2.4 Hz, 1H), 5.26 (s, 1H), 4.46 (t, J = 6.0 Hz, 2H), 4.15-3.95 (m, 1H), 3.77 (s, 3H), 3.31-3.21 (m, 1H), 3.19-3.07 (m, 1H), 2.84 (t, J = 6.0 Hz, 2H), 2.17 (s, 3H), 1.27 (s, 3H). ESI-MS (m / z): 606.15 (M+H)+. Using appropriate starting materials and suitable modifications of the process described for the preparation of Examples 1, 2 and 3 including suitable addition and / or deletion of steps as may be necessary, well within the scope of a person skilled in the art; the following compounds were prepared in an analogues manner. EXAMPLE 4 Preparation of 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- (s, , , 1.43 (s, 6H), 1.31(s, 3H), 1.18 (s, 3H). ESI-MS (m / z): 648.20 (M+H)+. EXAMPLE 5 Preparation of 2-(((3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin- 1-yl)ethyl)amino)-5-methoxybenzylidene)amino)oxy)-2-methylpropanoic acid Prepared using (DMSO-d6): 12.80 (s, 1H), 8.03-8.01 (d, J=8 Hz, 2H ), 7.58-7.56 ( d, J=8 2H ), 7.46-7.44 (d, J=8 Hz, 2H), 7.34-7.32 (d, , J= 8 Hz, 1H ),7.02-7.00 (d, J= 8 Hz,1H), 6.68-6.66 (d, J=8 Hz, 1H), 6.60 (s, 1H), 6.38-6.37 (m, 2H ), 5.57-5.55(d, J=8Hz, 1H), 4.55-4.50 (m ,1H), 4.04-3.97 (m ,1H), 3.656(s, 3H), 3.43-3.10 (m, 2H ), 1.44-1.40 (m, 6H). ESI-MS (m / z): 606.11 (M+H)+. EXAMPLE 6 Preparation of 3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid Prepared using (DMSO-d6): 8.00 (s, 1H), 7.60-7.57 (d, J= 12 Hz,2H), 7.46-7.44 (d, J= 8 Hz, 2H ), 7.39-7.37 (d, J= 8 Hz, 1H ), 7.07-7.05 ( d, J= 8 Hz, 1H ), 6.62 (s, 1H), 6.60-6.58 (d, J= 8 Hz, 1H ), 6.43 (s, 1H), 6.37(s, 1H), 5.64-5.62 (d, J=8Hz, 1H), 4.35-4.32 (d, J=12Hz, 1H ), 4.28-4.25 (t, J=6 Hz, 2H), 3.79-3.77 (d, J=8Hz, 1H), 3.67 (s, 3H), 2.60-2.56 (t, J=8 Hz, 2H), 2.05 (s, 3H), 1.31 (s, 3H), 1.20 (s, 3H). ESI-MS (m / z): 634.24 (M+H)+. EXAMPLE 7 Preparation of 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile Prepared using (CDCl3): 8.20 (s, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.4 Hz, 1H), 6.92 (d, J = 7.2 Hz, 1H), 6.62 (s, 1H), 6.53 (s, 1H), 6.27-6.26 (m, 1H), 5.24 (s, 1H), 4.80 (s, 2H), 4.41-4.34 (m, 1H), 4.02-3.98 (m, 1H), 3.78 (s, 3H), 3.28-3.22 (m, 1H), 3.15-3.09 (m, 1H), 2.19 (s, 3H). ESI-MS (m / z): 573.18 (M+H)+EXAMPLE 8 Preparation of 3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile

[0005] Prepared using inte NMR (DMSO-d6): 8.00 (s, 1H), 7.60-7.57 (d, J= 12 Hz, 2H), 7.47-7.45 (d, J= 8 2H), 7.39-7.37 (d, J= 8 Hz, 1H), 7.07-7.05 ( d, J= 8 Hz, 1H), 6.69 (s, 1H), 6.61-6.59 (d, J= 8 Hz, 1H), 6.48 (s, 1H), 6.39 (s, 1H), 5.65-5.63 (d, J=8 Hz, 1H), 4.34-4.32 (d, J=12Hz, 1H), 4.27-4.24 (t, J=6Hz, 2H), 3.79-3.76( d, J=8Hz, 1H), 3.67 (s, 3H), 2.90-2.87 (t, J=6 Hz, 2H), 2.12 (s, 3H), 1.23 (s, 3H),1.11 (s, 3H). ESI-MS (m / z): 615.23 (M+H)+. EXAMPLE 9 Preparation of 2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin- 1-yl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one Prepared using ( DMSO-d6): 8.0 (s, 1H), 7.59-7.57 (d, J=8.4 Hz, 2H), 7.46-7.44 (d, J=8.4 Hz, 2H), 7.39-7.37 (d, J=8 Hz, 1H), 7.07-7.04 (d, J=9.6 Hz, 1H), 6.64 (s, 1H), 6.58-6.56 (d, J=8 Hz, 1H), 6.42 (s, 1H), 6.53 (s, 1H), 5.60-5.58 (d, J=8 Hz, 1H), 4.58-4.55 (t, J=6 Hz, 1H), 4.31-4.29 (d, J=10.4 Hz, 1H), 3.80-3.78 (d, J=10.4 Hz, 1H), 3.67 (s, 3H), 3.41-3.40 (d, J=6 Hz, 2H), 2.05 (s, 3H), 1.31 (s, 1H), 1.19-1.17 (d, J=5.6 Hz, 9H). ESI-MS (m / z): 634.20 (M+H)+. EXAMPLE 10 Preparation of 2-(4-chlorophenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1- yl)ethan-1-one Prepared using (CDCl3): 8.20 (s, 1H), 7.48 (d, J = 8.8 Hz, 2H), 7.36 (d, J = 6.8 Hz, 2H), 7.15 (d, J = 8.4 Hz, 1H), 6.91 (dd, J = 1.2 & 9.2 Hz, 1H), 6.50 (dd, J = 1.6 & 4.8 Hz, 2H), 6.22 (t, J = 2.0 Hz, 1H), 5.20 (s, 1H), 4.40-4.34 (m, 2H), 4.02-3.95 (m, 1H), 3.77-3.72 (m, 5H), 3.30-3.23 (m, 1H), 3.21-3.08 (m, 1H), 2.16 (s, 3H), 1.33 (d, J = 7.6 Hz, 6H). ESI-MS (m / z): 606.15 (M+H)+. EXAMPLE 11 Preparation of 2-(4-chlorophenyl)-2-((3-(1-((2-hydroxyethoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one Prepared using intermediate IV-1 and intermediate V-7.1H NMR (CDCl3): 8.20 (s, 1H), 7.47 (dd, J = 1.6 and 6.4 Hz, 2H), 7.36 (dd, J = 2.0 and 6.4 Hz, 2H), 7.16 (d, J = 8.0 Hz, 1H), 6.94 (d, J = 1.2 Hz, 1H), 6.54-6.52 (m, 2H), 6.23-6.22 (m, 1H), 5.21 (s, 1H), 4.32-4.30 (m, 3H), 3.99-3.97 (m, 3H), 3.77 (s, 3H), 3.25-3.21 (m, 1H), 3.16-3.10 (m, 1H), 2.20 (s, 3H). ESI-MS (m / z): 578.18 (M+H)+EXAMPLE 12 Preparation of 3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile Prepared using (CDCl3): 8.19 (s, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.38-7.36 (m, 2H), 7.16 (d, J = 8.4 Hz, 1H), 6.92 (dd, J = 1.2 & 8.4 Hz, 1H), 6.64 (d, J = 1.6 Hz, 1H), 6.57-6.56 (m, 1H), 6.25-6.24 (m, 1H), 5.28 (s, 1H), 4.40-4.36 (m, 3H), 3.98-3.96 (m, 1H), 3.78 (s, 3H), 3.25-3.21 (m, 1H), 3.16-3.08 (m, 1H), 2.77 (t, J = 6.2 Hz, 2H), 2.19 (s, 3H). ESI-MS (m / z): 587.18 (M+H)+EXAMPLE 13 Preparation of 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid

[0006] Prepared using in NMR (CDCl3): 8.09 (s, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), (dd, J = 1.6 and 8.0 Hz, 1H), 6.90 (d, J = 6.8 Hz, 2H), 6.79 (bs, 1H), 6.61 (s, 1H), 6.38 (s, 1H), 5.83 (s, 1H), 4.48 (t, J = 5.8 Hz, 2H), 4.38-4.37 (m, 1H), 3.95 (s, 3H), 3.86-3.80 (m, 1H), 3.74 (s, 3H), 3.27-3.20 (m, 3H), 2.81 (t, J = 5.6 Hz, 2H), 2.18 (s, 1H). ESI-MS (m / z): 636.22 (M+H)+EXAMPLE 14 Preparation of 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile Prepared using NMR (CDCl3): 8.18 (s, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.15 (d, J = 8.0 Hz, 1H), 6.98-6.90 (m, 3H), 6.61-6.58 (m, 2H), 6.31-6.30 (m, 1H), 5.72 (s, 1H), 4.37 (t, J = 6.2 Hz, 2H), 4.31 (m, 1H), 4.00 (s, 3H), 3.91 (m, 1H), 3.78 (s, 3H), 1.25-1.17 (m, 1H), 1.04-1.14 (m, 1H), 2.78 (t, J = 6.2 Hz, 2H), 2.20 (s, 3H). ESI-MS (m / z): 617.20 (M+H)+EXAMPLE 15 Preparation of 2-(4-chloro-2-methoxyphenyl)-2-((3-(1-((2- hydroxyethoxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one Prepared using NMR (CDCl3): 8.09 (s, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H), 6.98-6.90 (m, 3H), 6.57 (s, 1H), 6.52 (s, 1H), 6.27 (s, 1H), 5.70 (s, 1H), 4.35-4.30 (m, 3H), 4.01 (s, 3H), 3.95-3.88 (m, 3H), 3.77 (s, 3H), 3.22-3.18 (m, 1H), 3.13-3.09 (m, 1H), 2.20 (s, 3H). ESI-MS (m / z): 608.22 (M+H)+EXAMPLE 16 Preparation of 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile Prepared using NMR (DMSO-d6): 7.99(s,1H), 7.39-7.33 (m, 2H), 7.16(s, 1H), 7.07-7.02 (t, J= 12 Hz, 2H), 6.46-6.60 (m, 2H), 6.49 (s, 1H ), 6.29 (s, 1H), 5.68-5.66 (d, J=8 Hz, 1H) 4.27-4.24 (t, J= 8 Hz, 2H) 4.14-4.11 (d, J=12 Hz, 1H), 3.92 (s, 3H), 3.87-3.84 (d, J=12 Hz, 1H), 3.67 (s, 3H) 2.89-2.87 (t, J=4 Hz, 2H), 2.11 (s , 3H), 1.35 (s, 3H), 1.23 (s, 3H). ESI-MS (m / z): 645.18 (M+H)+. EXAMPLE 17 Preparation of 2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)- amino)ethan-1-one Prepared using NMR ( DMSO-d6): 8.0 (s, 1H), 7.59-7.57 (d, J=8.4 Hz, 2H), 7.46-7.44 (d, J=8.4 Hz, 2H), 7.39-7.37 (d, J=8 Hz, 1H), 7.07-7.04 (d, J=9.6 Hz, 1H), 6.64 (s, 1H), 6.58-6.56 (d, J=8 Hz, 1H), 6.42 (s, 1H), 6.53 (s, 1H), 5.60-5.58 (d, J=8 Hz, 1H), 4.58-4.55 (t, J=6 Hz, 1H), 4.31-4.29 (d, J=10.4 Hz, 1H), 3.80-3.78 (d, J=10.4 Hz, 1H), 3.67 (s, 3H), 3.41-3.40 (d, J=6 Hz, 2H), 2.05 (s, 3H), 1.31 (s, 1H), 1.19-1.17 (d, J=5.6 Hz, 9H). ESI-MS (m / z): 664.21 (M+H)+. EXAMPLE 18 Preparation of 2-(4-chloro-2-methoxyphenyl)-2-((3-(1-(((1-hydroxy-2- methylpropan-2-yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one

[0007] Prepared using inte H NMR (CDCl3): 8.19 (s, 1H), 7.40-7.38 (d, J=8 Hz, 1H), 7.17-7.14 (d, J=8.4 Hz, 1H), 6.99-6.89 (m, 3H), 6.56-6.55 (d, J=1.2 Hz, 1H), 6.52 (s, 1H), 6.28-6.27 (t, J=2.4 Hz, 1H), 5.70 (s, 1H), 4.34-4.31 (m, 1H), 4.00 (s, 3H), 3.95-3.90 (m, 1H), 3.77 (s, 3H), 3.74 (s, 2H), 3.23- 3.20 (m, 1H), 3.13-3.09 (m, 1H), 2.81(s, 1H), 2.17 (s, 3H), 1.34-1.32 (d, J=5.6 Hz, 6H). ESI-MS (m / z): 636.20 (M+H)+. EXAMPLE 19 Preparation of 2-(4-chloro-2-methoxyphenyl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one Prepared using NMR (CDCl3): 8.19 (s, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.98-6.89 (m, 3H), 6.59 (s, 1H), 6.55 (s, 1H), 6.26 (t, J = 2.0 Hz, 1H), 5.70 (s, 1H), 4.40 (t, J = 6.2 Hz, 2H), 4.33- 4.32 (m, 1H), 4.01 (s, 3H), 3.95-3.91 (m, 1H), 3.77 (s, 3H), 3.22-3.20 (m, 1H), 3.11- 3.09 (m, 1H), 2.16 (s, 3H), 1.96 (t, J = 6.2 Hz, 2H), 1.34 (s, 6H). ESI-MS (m / z): 650.21 (M+H)+. EXAMPLE 20 Preparation of 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile Prepared using (DMSO-d6 ): 8.00 (s, 1H), 7.60-7.57 (d, J=8.4 Hz, 2H), 7.44-7.39 (d, J= 8.4 Hz, 2H), 7.37-7.21 (m, J=8.4 Hz, 1H 1H), 7.05-7.04 (m, 1H), 6.95 (s, 1H), 6.46 (m, 1H), 6.41 (s, 1H), 5.62 (s, 1H), 4.32-4.30 (d, J= 10.4 Hz, 1H), 3.79-3.77 (d, J= 10.4 Hz, 1H), 3.69 (s, 3H), 2.13 (s, 3H), 1.66 (s, 6 H), 1.24 (s, 3H), 1.17 (s, 3H). ESI-MS (m / z): 629.19 (M+H)+. EXAMPLE 21 Preparation of 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid Prepared using intermediate VI-1, intermediate V-1 and II-2. ESI-MS (m / z): 678.19 (M+H)+. EXAMPLE 22 Preparation of 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid Prepared using MS (m / z): 664.14 (M+H)+. EXAMPLE 23 Preparation of 2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin- 1-yl)-2-((3-(1-((2-hydroxyethoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1- one Prepared using (M+H)+. EXAMPLE 24 Preparation of 2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-((3-(1-((2-hydroxyethoxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one Prepared using MS (m / z): 636.11 (M+H)+. EXAMPLE 25 Preparation of 2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin- 1-yl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one Prepared using (M+H)+. EXAMPLE 26 Preparation of 2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one

[0008] Prepared using inte ESI-MS (m / z): 678.13 (M+H)+. EXAMPLE 27 Preparation of 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile Prepared using MS (m / z): 603.19 (M+H)+. EXAMPLE 28 Preparation of 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile

[0009] Prepared using intermediate IV-1, and intermediate V-9 ESI-MS (m / z): 601.15 (M+H)+. EXAMPLE 29 Preparation of 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile Prepared using MS (m / z): 631.18 (M+H)+. EXAMPLE 30 Preparation of 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile Cl Prepared using intermediate V-4 and IV-2. ESI-MS (m / z): 601.03 (M+H)+. EXAMPLE 31 Preparation of 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile Cl Prepared using MS (m / z): 631.15 (M+H)+. EXAMPLE 32 Preparation of 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile Cl Prepared using ESI-MS (m / z): 659.10 (M+H)+. EXAMPLE 33 Preparation of 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide To a stirring solution of the product obtained from example 2 (400 mg, 0.618 mmol) in DCM (15 mL) was added EDC.HCl (239 mg, 1.26 mmol) followed by DMAP (7.9 mg, 0.069 mmol) and the resulting mixture was stirred at room temperature for 1 hr. To this was added methane sulfonamide (118 mg, 1.24 mmol) and the resulting mixture was stirred at room temperature for 12 hrs. After complete conversion of the starting material, the reaction mixture was diluted with cold water, acidify with aqueous HCl and extracted with DCM. The organic layer was separated, washed with water and evaporated under reduced pressure to get crude product which was purified by column chromatography to get the title product.1H NMR (CDCl3): 8.18 (s, 1H), 7.37 (d, J =8.0 Hz, 1H), 7.15 (d, J =8.0 Hz, 1H), 6.98-6.90 (m, 3H), 6.61-6.58 (m, 2H), 6.31-6.30 (m, 1H), 5.72 (s, 1H), 4.37 (t, J =6.2 Hz, 2H), 4.31 (m, 1H), 4.00 (s, 3H), 3.91 (m, 1H), 3.78 (s, 3H), 1.25-1.17 (m, 1H), 1.04-1.14 (m, 1H), 2.78 (t, J = 6.2 Hz, 2H), 2.20 (s, 3H). ESI-MS (m / z): 727.20 (M+H)+EXAMPLE 34 Preparation of (2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propenamide Prepared using similar process as described for example 331H NMR (CDCl3):1H NMR (DMSO-d6): 11.04 (s, 1H), 8.03 (s, 1H), 7.57-7.55 (d, J=8.4 Hz, 2H), 7.45-7.43 (d, J=8.4 Hz, 2H), 7.35-7.32 (m, 1H), 7.30-7.29 (m, 1H), 7.02-7.00 (m, 1H), 6.63 (s, 2H), 6.39-6.37(d, J= 8.0 Hz, 2H), 5.77 (s, 1H ), 4.55-4.54 (t, J=2.0 Hz, 1H), 4.05-4.03 (m, 1H), 3.66 (s, 3H), 3.20 (s, 3H), 3.15-314 (m, 2H), 2.10 (s, 3H), 1.48 (s, 6H). ESI-MS (m / z): 697.20 (M+H)+. EXAMPLE 35 Preparation of 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide

[0010] Prepared using e ng similar process as described for example 33.1H NMR (DMSO-d6): 11.50 (s, 1H), 8.00 (s, 1H), 7.58-7.56 (d, J=8 Hz 2H), 7.45-7.42 (m , 2H), 7.39-7.37 (d, J=8 Hz, 1H), 7.07-7.05 (d, J=8 Hz, 1H), 6.69-6.61 (m, 2H ), 6.41-6.40 (m, 2H), 5.57-5.55 (d, J=8 Hz, 1H), 4.30-4.28 ( d, J=8 Hz, 1H), 3.80-3.77 (d, J=8 Hz, 1H), 3.65 (s, 3H), 3.21 (s, 3H), 2.16 (s, 3H), 1.45- 1.47 (d, J=4 Hz, 6H), 1.31 (s, 3H), 1.18 (s, 3H). ESI-MS (m / z): 725.19 (M+H)+. EXAMPLE 36 Preparation of 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propenamide Prepared using similar process as described for example 33. ESI-MS (m / z): 755.12 (M+H)+. EXAMPLE 37 Preparation of 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-N-(cyanomethyl)-2-methylpropanamide Prepared using similar process as described for example 33 .1H NMR (CDCl3): 8.17 (s, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.16 (d, J =8.0 Hz, 1H), (dd, J =2.0 & 8.4 Hz, 1H), 6.94-6.91 (m, 2H), 6.69-6.62 (m, 3H), 6.36 (s, 1H), 5.73 (s, 1H), 4.30 (m, 1H), 4.18-4.16 (m, 2H), 3.95 (s, 3H), 3.90- 3.83 (m, 1H), 3.77 (s, 3H), 3.12-3.08 (m, 2H), 2.23 (s, 3H), 1.56 (s, 3H), 1.53 (s, 3H). ESI-MS (m / z): 688.25 (M+H)+EXAMPLE 38 Preparation of (2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-N-(cyanomethyl)-2-methylpropanamide Prepared using similar process as described for example 33 .1H NMR (CDCl3): 8.17 (s, 1H), 7.47 (d, J =8.8 Hz, 2H), 7.36 (d, J =8.4 Hz, 2H), 7.16 (d, J = 8.0 Hz, 1H), 6.91 (d, J =7.2 Hz, 1H), 6.67 (s, 1H), 6.59 (t, J =6.0 Hz, 1H), 6.53 (s, 1H), 6.28 (d, J = 2.0 Hz, 1H), 5.30 (s, 1H), 4.40-4.39 (m, 1H), 4.29-4.23 (m, 1H), 4.13-4.07 (m, 1H), 3.94-3.92 (m, 1H), 3.77 (s, 3H), 3.28- 3.27 (m, 1H), 3.11-3.10 (m, 1H), 2.22 (s, 3H), 1.56 (s, 3H), 1.50 (s, 3H). ESI-MS (m / z): 658.24 (M+H)+EXAMPLE 39 Preparation of (2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoyl)glycine Step 1: -2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoyl)glycinate To a stirring gm, 0.867 mmol) and methyl glycinate hydrochloride (0.131 gm, 1.04 mmol) in DCM (10 ml) was added DIPEA (0.3 ml, 1.733 mmol) dropwise and stirred for 5 min at room temperature. EDC.HCl (0.25 gm, 1.3 mmol) and HOBT (0.027 gm, 0.173 mmol) were added to the reaction mixture and stirred at room temperature for 3 hrs. After the complete conversion of the starting material, the reaction mixture was diluted cold water and extracted by DCM. The organic layer was separated and evaporated under reduced pressure and purified by column chromatography to get the title product. Step 2: 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoyl)glycine To a stirring 0.525 mmol) in THF:Water (3:3 ml) was added LiOH (0.038 gm, 1.574 mmol) in water (1 ml) at 5- 10oC and the resulting reaction mixture was stirred at room temperature for 2 hrs. After the complete conversion of the starting material, the solvent was evaporated under reduced pressure and the obtained material was diluted with water and acidified up to pH-6 using citric acid. Obtained solid material was filtered off, washed with water, dried and purified by column chromatography to get the title product.1H NMR (CDCl3): 8.17 (s, 1H), 7.45 (d, J=8.4 Hz, 2H), 7.34 (d, J=8.4 Hz, 2H), 7.16 (d, J=8.4 Hz, 1H), 6.94-6.92 (m, 2H), 6.82 (s, 1H), 6.55 (s, 1H), 6.27 (s, 1H), 5.33 (s, 1H), 4.39- 4.36 (m, 1H), 4.15-4.09 (m, 2H), 3.96-3.94 (m, 1H), 3.76 (s, 3H), 3.27-3.25 (m, 1H), 3.15-3.09 (m, 1H), 2.23 (s, 3H), 1.58 (s, 3H), 1.56 (s, 3H). ESI-MS (m / z): 677.23 (M+H)+EXAMPLE 40 Preparation of 3-(((1-(3-((1-(4-chlorophenyl)-2-(indolin-1-yl)-2-oxoethyl)amino)- 5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid

[0011] Prepared using inter 22.12 (M+H)+EXAMPLE 41 Preparation of 2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one Prepared using (CDCl3): 8.19 (s, 1H), 7.47 (d, J=8.4 Hz, 2H), 7.36 (dd, J=1.6 & 6.4 Hz, 2H), 7.16 (d, J=8.0 Hz, 1H), 6.92 (dd, J=1.2 & 8.0 Hz, 1H), 6.55 (dd, J=1.6 & 13.6 Hz, 2H), 6.23 (t, J=2.2 Hz, 1H), 5.26 (s, 1H), 4.42-4.35 (m, 3H), 4.01-3.94 (m, 1H), 3.77 (s, 3H), 3.25-3.21 (m, 1H), 3.14-3.08 (m, 1H), 2.16 (s, 3H), 1.99 (t, J=6.0 Hz, 2H), 1.33 (d, J=4.0 Hz, 6H). ESI- MS (m / z): 620.16 (M+H)+. EXAMPLE 42 Preparation of (+) 2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one

[0012] Enantiomer of ex (Column-Chiral PAK IG(250*30) mm*10µ(Diacel), in n-hexane and 2-propanol Isocratic Elution (60:40), Wavelength-210nm). (t=49.34 min; ee=100%).1H NMR ( DMSO-d6): 8.03 (s, 1H), 7.59-7.57 (d, J=8.8 Hz, 2H), 7.46-7.44 (d, J=8.8 Hz, 2H), 7.34-7.32 (d, J=8.4 Hz, 1H), 7.02-7.00 (m, 1H), 6.66 (s, 1H), 6.60-6.58 (d, J=8.4 Hz, 1H), 6.43-6.42 (t, J=2 Hz, 1H), 6.35-6.34 (d, J=2 Hz, 1H), 5.61-5.59 (d, J=8.4 Hz, 1H), 4.62-4.54 (m, 1H), 4.29 (s, 1H), 4.20-4.16 (t, J=7.2 Hz, 2H), 4.05-4.03 (m, 1H), 3.67 (s, 3H), 3.20-3.16 (m, 2H), 2.06 (s, 3H), 1.76-1.73 (t, J=7.2 Hz, 2H), 1.128-1.125 (d, J=1.6 Hz, 6H). ESI-MS (m / z): 620.20 (M+H)+. EXAMPLE 43 Preparation of (-) 2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one Enantiomer of Chiral PAK IG(250*30) mm*10µ(Diacel), in n-hexane and 2-propanol Isocratic Elution (60:40), Wavelength-210nm). (t=31.16 min; ee=98.49%).1H NMR ( DMSO-d6): 8.03 (s, 1H), 7.59-7.57 (d, J=8.8 Hz, 2H), 7.46-7.44 (d, J=8.8 Hz, 2H), 7.34-7.32 (d, J=8.4 Hz, 1H), 7.02-7.00 (m, 1H), 6.66 (s, 1H), 6.60-6.58 (d, J=8.4 Hz, 1H), 6.43-6.42 (t, J=2 Hz, 1H), 6.35-6.34 (d, J=2 Hz, 1H), 5.61-5.59 (d, J=8.4 Hz, 1H), 4.62-4.54 (m, 1H), 4.29 (s, 1H), 4.20-4.16 (t, J=7.2 Hz, 2H), 4.05-4.03 (m, 1H), 3.67 (s, 3H), 3.20-3.16 (m, 2H), 2.06 (s, 3H), 1.76-1.73 (t, J=7.2 Hz, 2H), 1.128-1.125 (d, J=1.6 Hz, 6H). ESI-MS (m / z): 620.20 (M+H)+. Using suitable modifications of the process described above following compounds were prepared. Example NAME ESI-MS N 48 (+) 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- 648.20 (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- 55 (-) 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2- 636.22 (6-(trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide 69 (-) 3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- 587.20 77 (-) 2-(4-chlorophenyl)-1-(3,3-dimethyl-6- 634.18 (trifluoromethoxy)indolin-1-yl)-2-((3-(1-(((1-hydroxy-2- 84 (+) 2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)-1- 620.18 92 (+) 3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- 615.21 100 (+) 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- 601.12 (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- 107 (-) 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3- 659.19 dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- Assy protocol to screen compounds using RT-PCR VeroE6 cells, mycoplasma free are seeded at the density of 25,000 cells / well in 100 µl / well in 96 well plate in complete MEM (Plain MEM + 10% FBS+ 1X antibiotics) and incubated overnight at 37 °C, 5% CO2. Next day, the required virus (DENV2 NGC Strain -New Guinea C) of 106PFU / mL in plain MEM at 0.05 MOI is added to the cells and incubated for 1 h at 37°C, 5% CO2. After 1 h, virus was removed and compounds were added at required concentrations. After 48 h, RNA was isolated from the supernatant. It is then reverse transcribed to cDNA and amount of virus detected by RT-PCR. Following the denaturation at 95 °C for 5 minutes, the RT-PCR was run for 45 cycles for 95 °C for 10 second, 60 °C 30 second. Delta delta CT was calculated for all CT values. % inhibition was calculated by considering DMSO delta delta CT as 100-% inhibition. Inhibitory concentration (50%) was derived from plotting the data in Graph pad prism and performing non-linear regression analysis. Biological Data: Example No DENV2 IC50(nM) 8 5 11 16 Examples 7, 9 , , , , , , , , , , , , , , , 0, 31, 32, 36, 40, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107 have shown DENV2 IC50 value in the range of less than 200 nM. The novel compounds of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known. The novel compounds of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs are useful as a medicament for the mammalian infections and suitable for humans and other warm- blooded animals, and may be administered either by oral, topical or parenteral administration. The quantity of the active component, that is, the novel compounds of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts, their polymorphs and unit dosage form thereof may be varied or adjusted widely depending upon several factors such as the particular application method, the potency of the particular compound and the desired concentration. Use of the novel compounds of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs for the treatment of virus-related disorders such as Dengue. A method of treatment of virus-related disorders such as Dengue by administering to a subject in need thereof a therapeutically effective amount of formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs.

Claims

We claim:

1. A novel compound of the general formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs,X is selected from aryl, heteroaryl or heterocyclyl ring; R1 is selected from hydrogen, halogen, haloalkyl, (C1-C6)alkyl, heterocyclyl, - OR6; where (C1-C6)alkyl, heterocyclyl are independently unsubstituted or substituted with one or more suitable substituents; Y1 and Y2 are selected from hydrogen, fluoro, (C1-C6)alkyl and -OR6; A and B are selected from carbocyclic or heterocyclic ring; R2and R3are selected from hydrogen, hydroxy, cyano, halo, nitro, haloalkyl, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy, -COR6, - COOR6, -OR6, -OSO2CH3, -OCOR6, -S(O)pR6, -NR6R7, -CONR6R7, - N(R6)COR7, -N(R6)COOR7, -N(R6)CONR6R7, -SO2NR6R7, -N(R6)SO2R7; which are independently unsubstituted or substituted with one or more suitable substituents;R4is selected from hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, haloalkyl and heterocyclyl, which are independently unsubstituted or substituted with one or more suitable substituents; R5is selected from haloalkyl, (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, which are independently unsubstituted or substituted with one or more suitable substituents; R6and R7are independently selected from hydrogen, unsubstituted or substituted (C1-C6)alkyl, (C3-C6)cycloalkyl, haloalkyl; R6and R7together with the N atom to which they are attached may form a 5-8 membered heterocyclyl or heteroaryl ring; when any of the (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- C6)cycloalkyl are substituted; the suitable substitutions on them may be selected from hydrogen, hydroxy, cyano, halo, nitro, haloalkyl, oxo, (C1- C6)alkyl, (C3-C6)cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heterocyclylalkyl, alkylsulfonyloxy, -COR6, -COOR6, -OR6, -S(O)pR6, -NR6R7, -CONR6R7, -CON(R6)OR7, -CON(R6)SO2R7, -N(R6)COR7, -N(R6)COOR7, - N(R6)CONR6R7,-SO2NR6R7, -N(R6)SO2R7derivatives; R6and R7are same as described above; p is selected from integers from 0-2; l is selected from integers from 1-4; m is selected from integers from 1-5; n is selected from integers from 1-4.

2. The compound of formula (I) as claimed in claim 1, wherein X is aryl; R1 is - OR6; Y1and Y2are hydrogen; A and B are selected from carbocyclic ring; R2and R3 are selected from halo, -OR6; R4 and R5 are selected from hydrogen,unsubstituted or substituted (C1-C6alkyl); R6and R7are selected from hydrogen, unsubstituted or substituted (C1-C6 alkyl).

3. Compounds of the formula (I) as claimed in claim 1: 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; 3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1- yl)-2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2- methylpropanoic acid; 2-(((3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxybenzylidene)amino)oxy)-2-methylpropanoic acid; 3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1- yl)-2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)acetonitrile; 3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1- yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; 2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2-((3- (1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one;2-(4-chlorophenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one; 2-(4-chlorophenyl)-2-((3-(1-((2-hydroxyethoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; 3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; 2-(4-chloro-2-methoxyphenyl)-2-((3-(1-((2-hydroxyethoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; 2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin- 1-yl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one;2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1- yl)-2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2- methylpropanenitrile; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; 3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; 2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2-((3- (1-((2-hydroxyethoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one; 2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin- 1-yl)-2-((3-(1-((2-hydroxyethoxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one; 2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2-((3- (1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan- 1-one; 2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin- 1-yl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile; 2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2- methylpropanenitrile; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile;2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1- yl)-2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)acetonitrile; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propenamide; (2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propenamide; 2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1- yl)-2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propenamide; 2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-N-(cyanomethyl)-2- methylpropanamide; (2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-N-(cyanomethyl)- 2-methylpropanamide;(2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2- methylpropanoyl)glycine; 3-(((1-(3-((1-(4-chlorophenyl)-2-(indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; 2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid;(+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanoic acid; (+)-3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (-)-3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (+)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (-)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (+)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (-)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (+)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid; (-)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanoic acid;(+)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide ; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2-methyl-N- (methylsulfonyl)propanamide; (+)-3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (-)-3-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (+)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (-)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (+)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (-)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (+)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (-)-3-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (+)-2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- ((3-(1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one;(-)-2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- ((3-(1-(((1-hydroxy-2-methylpropan-2-yl)oxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(1-(((1-hydroxy-2-methylpropan-2- yl)oxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (-)-2-(4-chlorophenyl)-2-((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)-1-(6-(trifluoromethoxy)indolin-1-yl)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one;(-)-2-(4-chloro-2-methoxyphenyl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)-1-(6- (trifluoromethoxy)indolin-1-yl)ethan-1-one; (+)-2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- ((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one; (-)-2-(4-chlorophenyl)-1-(3,3-dimethyl-6-(trifluoromethoxy)indolin-1-yl)-2- ((3-(1-((3-hydroxy-3-methylbutoxy)imino)ethyl)-5- methoxyphenyl)amino)ethan-1-one; (+)-2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one; (-)-2-(4-chloro-2-methoxyphenyl)-1-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-((3-(1-((3-hydroxy-3- methylbutoxy)imino)ethyl)-5-methoxyphenyl)amino)ethan-1-one; (+)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (-)-3-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)propanenitrile; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile;(+)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2- methylpropanenitrile; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1- yl)ethyl)amino)-5-methoxyphenyl)ethylidene)amino)oxy)-2- methylpropanenitrile; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6- (trifluoromethoxy)indolin-1-yl)ethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (-)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)acetonitrile; (+)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile;(-)-2-(((1-(3-((1-(4-chlorophenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (+)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile; (-)-2-(((1-(3-((1-(4-chloro-2-methoxyphenyl)-2-(3,3-dimethyl-6- (trifluoromethoxy)indolin-1-yl)-2-oxoethyl)amino)-5- methoxyphenyl)ethylidene)amino)oxy)-2-methylpropanenitrile.

4. Use of the novel compound of general formula (I) as claimed in claim 1 for the treatment of virus-related disorder selected from dengue.

5. Use of the compound of general formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs as claimed in claim 1 in the manufacture of a medicament for the treatment of virus-related disorder selected from dengue.

6. Pharmaceutical compositions comprising compounds of general formula (I), their tautomeric forms, their stereoisomers, their suitable pharmaceutically acceptable salts and their polymorphs as claimed in claim 1 and their mixtures having pharmaceutically acceptable carriers, solvents, diluents, binder, disintegrant, coating agent, filler, glidant, and / or other suitable excipients.

Images